Neurological Institute Outcomes
Movement Disorders
Huntington Disease
Cleveland Clinic's Neurological Institute has been designated as a Huntington's Disease Society of America Center of Excellence.
Change in Depressive Symptoms in Huntington Disease (N = 53)
2021 – 2022
HD = Huntington Disease, PHQ-9 = Patient Health Questionnaire
Fifty-three patients with Huntington disease (HD) completed the PHQ-9 at least twice in 2021-2022, with the first follow-up in 2022. The median duration of follow-up was 304 days (range, 69-663 days). Of those, 24 (45.3%) improved, 23 (43.3%) remained stable, and 6 (11%) worsened. A change of 5 points is considered clinically significant in patients whose initial PHQ-9 is ≥ 10.¹
Change in PROMIS® Global Health Ratings for Patients With Huntington Disease (N = 46)
2021 – 2022
HD = Huntington disease, PROMIS = Patient-Reported Outcomes Measurement Information System
The PROMIS-10 questionnaire is a self-reported measure of physical and emotional health status reflecting health-related quality of life. Forty-six HD patients completed the PROMIS-10 at least twice in 2021-2022 and the second follow-up in 2022. The median duration of follow-up was 321days (range, 69-552 days). A clinically meaningful change was defined as a total change of > 5 T-score points.² Of the 46 patients, 14 (30.4%) improved, 28(60.9%) remained stable, and 4 (8.7%) worsened.
